Diwakar Gupta to join Alkem Labs as Independent Director
Maharashtra: Alkem Labs has announced the appointment of Diwakar Gupta as Additional Director designated as an Independent Director on the Board of Directors of the Company for a term of 5 (five) consecutive years, with effect from 13th July, 2025 upto 12th July, 2030.
Diwakar Gupta is a career banker with over 50 years of experience in banking and financial services. He is currently serving as a Non Executive Chairman of National Asset Reconstruction Company Limited and a Senior Advisor with True North, a leading India-focused PE fund. He is also serving as an Independent Director on the Boards of CRISIL Ratings Ltd, CRISIL ESG Ratings & Analytics Ltd., Mahindra Holidays & Resorts India Ltd. and its Finland based subsidiary, Holiday Club Resorts Oy, Mahindra Susten, Mahindra & Mahindra Financial Services Ltd., and SMFG India Credit Company (erstwhile FICC).
He has been closely associated with the RBI and various other governmental agencies throughout his career.
Read also: Cybersecurity incident at Alkem Labs US arm, investigation underway
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
